期刊文献+

p53蛋白表达与上皮性卵巢癌恶性程度及预后的关系研究 被引量:8

The significance of p53 in epithelial ovarian carcinoma prognosis and clinicopathology
下载PDF
导出
摘要 目的:研究p53蛋白表达与上皮性卵巢癌恶性程度及预后的关系。方法:采用免疫组化SP法测定26例上皮性卵巢癌中p53蛋白表达。结果:p53蛋白在黏液性、浆液性、内膜样卵巢癌中的表达率(88.9%、75%、100%)无明显差异(P>0.05);三种卵巢癌的复发率分别为33.3%、12.5%、0,以黏液性癌最高,三者之间有显著差异(P<0.05);p53蛋白在淋巴结转移卵巢癌患者中均为高表达(100%),与无淋巴结转移者(68.75%)相比差异明显(P<0.05);另外,淋巴结转移卵巢癌患者的复发率(40%)较无淋巴结转移患者(6.25%)明显增高(P<0.05)。p53蛋白在I-II期和III-IV期卵巢癌的高表达(50%、100%)具有显著差异(P<0.01),不同期别卵巢癌复发的几率也存在显著差异,其中I-II期复发率为0,III-IV期复发率为31.25%。结论:p53蛋白的高表达与上皮性卵巢癌的恶性程度及预后有着密切的关系。 Objective: To investigate the significance of p53 expression of epithelial ovarian carcinoma.Methods:To use immunohistoehemical method to detect the p53 expression in 26 patients with epithelial ovarian carcinoma.Results: The expression of p53 protein in epithelial ovarian cancer(pituita,serosity,intima) had no significant difference(88.9%,75%,100%)(P 0.05) in these three groups,while the recurrence rates among three cancer subtypes were significantly different(33.3%,12.5%,0).p53 protein expression in patients with lymph node metastasis was very strong(100%),and there was significant difference between the former and that without lymph node metastasis(68.75%)(P 0.05).The recurrence rate of the patients with lymph node metastasis(40%) was higher than that without lymph node metastasis(6.25%),(P 0.05).The high expression of p53 protein in ovarian cancer between I-II(50%) stage and III-IV stage(100%) was significantly different(P 0.05),and the recurrence rate was different(P 0.05).Conclusion: The expression of p53 protein has relationship with malignancy degree and prognosis of ovarian cancer.
出处 《现代肿瘤医学》 CAS 2012年第4期791-794,共4页 Journal of Modern Oncology
关键词 卵巢癌 P53 免疫组化 ovarian cancer p53 immunohistochemistry
  • 相关文献

参考文献4

二级参考文献27

  • 1王建华,张涛,纪宗正,贡桑明久,王小强,张小燕.应用噻唑蓝比色法进行大肠癌与胆囊癌细胞生长曲线的对比测定[J].现代肿瘤医学,2005,13(3):310-312. 被引量:5
  • 2Mazars R, Pujol P, Maudelonde T, et al. p53 mutations in ovarian caneer:a late event. [J] Oneogene,1991,6(9) :1685-1690.
  • 3Kohler MF, Kems BJ, Humphrey PA, et al. Mutation and overexpmssion of p53 in early-stage epithelial ovarian cancer[ J]. Obstet Gynecol, 1993,81 (5) :643-650.
  • 4Levine A J, Momand J, Finlay CA. The p53 tumour suppressor gone [J]. Nature,1991,351 (6326) :453-456.
  • 5大肠癌病理与预后关系研究协作组.国人青年大肠癌的特点和预后-319例病理分析[J].中华肿瘤杂志,1986,8(2):146-149.
  • 6Jass JR, Mukawa K,Goh H, et al. Clinical importance of DNA content in rectal cancer measured by flow cytometry,J Clin Pathol,1989,42(3):254.
  • 7Giaretti W, Danova M, Geido E, et al. Flow cytometry DNA index in the prognosis of colorectal cancer. Cancer.1991,67:1981.
  • 8Elias C, Oscar de la CM, Rose M, et al. Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinomas.Cancer Res,1991,51:4436.
  • 9Goh H, Chan CS, Khine K, et al. p53 and behaviour of colorectal cancer.Lancet.1994,344:233.
  • 10Swisher SG,Roth JA.Clinical update of Ad-p53 gene therapy for lung cancer[J].Surg Oncol Clin N Am,2002,11(3):521-535.

共引文献16

同被引文献55

  • 1杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量:1480
  • 2周一平,叶又蓁,孙志强,陈小可,彭蕻琳.909例胸腔积液病因与诊断分析[J].新医学,2005,36(6):327-328. 被引量:84
  • 3连利娟.林巧稚妇科肿瘤学[M].北京:人民卫生出版社,2011:540-555.
  • 4朱兰,沈铿,郎景和,黄荣丽,黄惠芳.卵巢上皮癌合并胸水的处理[J].中华医学杂志,1997,77(5):398-398. 被引量:7
  • 5Garcia RL,Coltrera MD,Gown AM.Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed,embedded tissues.Comparison with flow cytometric analysis[J].Am J Pathol,1989,134(4):733-739.
  • 6Gu J,Zhang L,Swisher SG,et al.Induction of p53-regulated genes in lung cancer cells:implications of the mechanism for adenoviral p53-mediated apoptosis[J].Oncogene,2004,23(6):1300-1307.
  • 7Kenemans P,Yedema CA,Bon GG,et al.CA 125 in gynecological pathology-areview[J].Eur J Obstet Gynecol Reprod Biol,1993,49(1-2):115-124.
  • 8Cimoli G,Valenti M,Ottoboni C,et al.HPV16-E6 enhances mitoxantrone sensitivity in a human ovarian cancer line:an isolated instance or a trend?[J].Int J Oncol,2001,18(4):759-765.
  • 9Nakeyama K,Tokebayashi Y,Nakayama S,et al.Pro-gonostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin[J].Cancer Left,2003,192(2):227-235.
  • 10Nakayama K,Takebayashi Y, Nakayama S, et al. Prognostic value of overexpression of P53 in human carcinoma patients receiving eiplatir[ J ]. Cancer Lett,2003,192 (2) :227-235.

引证文献8

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部